Mindpeak and Revolune Announce Commercial Co-Selling Partnership to Deliver End-to-End Spatial Biology Solutions

September 21, 2026

Partnership combines Mindpeak’s PhenoScout™ AI image analysis with Revolune’s multiplex IF kits to streamline the path from tissue staining to spatial discovery.

Hamburg, Germany - September 21, 2026 - Mindpeak, a leader in clinical-grade artificial intelligence for digital pathology, and Revolune, an innovator in accessible multiplex immunofluorescence (mIF) technologies, today announced a commercial co-selling partnership to offer an integrated workflow combining multiplex tissue staining with AI-powered image analysis.

Under the agreement, Mindpeak’s PhenoScout™ AI platform will be offered directly alongside Revolune’s multiplex reagent kits, providing researchers with an integrated path from tissue staining to spatial insights.

From Multiplex Staining to Spatial Insights

Multiplex immunofluorescence is transforming the way researchers characterize the tumor immune microenvironment, evaluate antibody-drug conjugates (ADCs), and identify translational biomarkers. As spatial biology continues to advance, researchers need workflows that make it easier to generate, interpret, and act on multiplex data with confidence.

The Revolune–Mindpeak partnership brings these capabilities together in one streamlined workflow:

Flexible Multiplex Staining:
Revolune enables laboratories to move quickly from validated primary antibodies to ready-to-use 4- to 7-plex kits without complex assay development.

Turnkey AI Analysis:
PhenoScout AI by Mindpeak automates cell detection, tumor/stroma segmentation, phenotyping, and spatial neighborhood metrics in minutes, eliminating the need for bioinformatics pipelines or manual thresholding.

“Multiplex immunofluorescence shouldn’t become complicated at the analysis step,” said Adrian Arechiga, CCO of Revolune. “Revolune removes the complexity of generating high-quality mIF data. By co-selling Mindpeak’s PhenoScout AI, we provide an integrated workflow that takes researchers from antibody staining to quantitative spatial data in minutes, enabling cohort-scale studies without bioinformatics backlogs.”

“Mindpeak was founded to bring precision, reproducibility, and automation to cellular pathology,” said Felix Faber, CEO of Mindpeak. “PhenoScout delivers turnkey spatial analysis out of the box using pre-trained foundation models. Partnering with Revolune creates an ideal synergy, pairing validated staining chemistry directly with fast, reproducible AI analysis.”

Evaluate the Integrated Workflow

To mark the launch, researchers purchasing qualifying Revolune multiplex IF kits will receive promotional PhenoScout AI analysis credits.

The introductory offer gives translational research teams and CROs the opportunity to evaluate the complete stain-to-insight workflow on their own tissue samples before transitioning to flexible annual subscription packages.

Explore the integrated workflow

PhenoScout AI is developed by Mindpeak and available through Revolune. For Research Use Only (RUO).

‍

About Revolune

Revolune is a life science company dedicated to making multiplex immunofluorescence as accessible and practical as routine tissue analysis. Its reagent technologies help laboratories move rapidly from existing primary antibodies to ready-to-use multiplex kits, simplifying spatial biology workflows and enabling researchers to focus on biological questions rather than assay management.

‍

About Mindpeak

Mindpeak is a leading company in AI-powered digital pathology, bridging the gap from biomarker development to clinical diagnostics. Founded in 2018, Mindpeak’s AI technology enables laboratories to extract actionable insights from H&E, IHC and mIF tissue images — ranging from subcellular biomarker quantification to predictive patient stratification. The solutions support both routine diagnostics and the translation of novel biomarkers into real-world clinical applications.

‍

Press Release

Related reading

Press Release
8 min read

PhenoScout AI: Advancing mIF Analysis

We’re proud to introduce PhenoScout AI, our next-generation multiplex immunofluorescence (mIF) analysis solution.

By automating phenotype identification, biomarker quantification, and spatial readouts, PhenoScout AI reduces variability and supports large-scale studies. The solution is designed for pharma, diagnostics, and academic research to accelerate translational medicine.

👉 Learn more

‍

Press Release
8 min read

Mindpeak Welcomes Christiaan Neeleman to the Board of Directors

We are delighted to announce that Christiaan Neeleman has joined Mindpeak’s Board of Directors.

With more than 20 years of international leadership experience in life sciences, diagnostics, and health technology - including senior roles at Discovery Life Sciences, Definiens, and Philips Healthcare - Christiaan brings deep expertise that will help accelerate our global expansion.

His proven track record in biomarker development, companion diagnostics, and scaling precision diagnostics businesses aligns perfectly with Mindpeak’s mission: enabling faster, more accurate cancer diagnostics through AI-powered pathology.

We are excited to collaborate with Christiaan as we strengthen partnerships, expand into new markets, and further drive the adoption of AI across clinical and research settings.

Read the full press release here

‍

‍

Press Release
8 min read

Expanding Global Access to AI Diagnostics – Our New Partnership with Pathomation

At Mindpeak, our vision is clear: world-class AI diagnostics should be available to every pathology lab, everywhere. By partnering with leading technology providers, we’re removing barriers to adoption and making AI-powered precision diagnostics a practical reality for labs worldwide.

Seamless AI Integration with Pathomation

Through our strategic collaboration with Pathomation, a globally trusted provider of digital pathology platforms, Mindpeak’s CE-IVD certified AI algorithms – including Ki-67, HER2, and zero-click PD-L1 scoring across multiple tissue types – are now natively integrated into Pathomation’s solutions.

This partnership means laboratories can:

  • Adopt advanced AI instantly – No extra development, integrations, or technical overhead required.
  • Work within existing workflows – Our algorithms run directly inside Pathomation’s widely adopted platform.
  • Deliver faster, more consistent results – Helping pathologists make confident, high-quality diagnostic decisions for patients everywhere.

Reaching More Labs, Globally

Pathomation’s worldwide presence, with distributor networks and users spanning Europe, Asia, and Latin America, ensures that AI-powered image analysis is accessible to more labs and more patients across the globe. Together, we’re removing geographic and technical barriers to bring state-of-the-art diagnostics to every corner of the world.

“Every partnership we form moves us closer to our goal: AI-powered image analysis in every lab, for every patient. Our collaboration with Pathomation is an important step toward making this vision a reality.” – Felix Faber, CEO, Mindpeak

‍

🔗 Learn more about the partnership and read the full press release: https://tissuepathology.com/2025/08/21/pathomation-and-mindpeak-forge-strategic-partnership-to-accelerate-ai-adoption-in-digital-pathology-workflows/

‍
‍

Ready to advance your diagnostics

Connect with our team to explore how precision pathology works in your setting